[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-op-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-op-complication":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,70,95,117,153,179,207,238,263],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100585631","phase-2-safety-and-efficacy-of-crofelemer-in-adult-patients-with-short-bowel-syndrome-and-intestinal-failure-sbs-if-without-colon-in-continuity-cic-100585631",false,"NCT06904872","Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)","A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)","CRO-SBS-IF","Inclusion Criteria\n\nPatients will be enrolled in the study if they meet all the following criteria:\n\n1. Patients must understand and provide written informed consent before they can participate in the study. They must understand the study procedures and be willing to complete the required assessments;\n2. Male and female patients aged ≥ 18 years;\n3. SBS patients with intestinal failure and without colon-in-continuity who are not eligible or not willing to receive an approved marketed GLP-2;\n4. Patients with history of SBS resulting in intestinal failure caused by a major intestinal resection (e.g., injury, cancer\\*, Crohn's disease, vascular disease, volvulus) without colon-in-continuity (patients with duodenostomy, Jejunostomy or Ileostomy). Intestinal failure will be defined according to the recommendations of the European Society for Clinical Nutrition and Metabolism (ESPEN), i.e., a reduction of gut function below the minimum necessary for the absorption of macronutrients and\u002For water and electrolytes, such that intravenous (IV) supplementation is required to maintain health and\u002For growth. \\*Patients with history of cancer, should be in remission for the last 6 months and with not ongoing anticancer therapy (long-term hormonal therapy is allowed).\n5. Minimum remaining length of 60 cm of small bowel;\n6. At least 6 months elapsed since last surgical bowel resection;\n7. No restorative surgery planned during the entire study period;\n8. Patients with at least 4 continuous months of PS dependency (parenteral nutrition with or without intravenous fluids);\n9. Chronic non-infectious diarrhoea defined as passage of at least 1 loose watery stool per day for more than 4 consecutive weeks.\n10. Patients receiving parenteral support (fluids, electrolytes and\u002For nutrients) for at least three days per week and a minimum of 6 liters of PS per week, to meet caloric, fluid or electrolytes needs;\n11. Patients with Crohn's disease will have to be in clinical remission for ≥ 12 weeks;\n12. Patients must be able to ingest solid or semi-solid foods and drink fluids;\n13. If taken at screening, use of antimotility and antidiarrheal agents (loperamide, diphenoxylate, codeine and other opiates), H2-receptor antagonists, proton pump inhibitors, bile sequestering agents, oral glutamine, diuretics and oral rehydration solutions is required to be at stable average weekly doses for at least 4 weeks prior to screening evaluations;\n14. If female and of child-bearing potential, the patient must use an \"acceptable effective contraceptive measure\" for the entire study duration and for 4 weeks after the last dose. Acceptable birth control methods that result in a failure rate of more than 1% per year include: progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action male or female condom with or without spermicide cap, diaphragm or sponge with spermicide (A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods) are also considered acceptable). Male patients must agree to use an acceptable form of birth control and to not donate sperm during the study and for 4 weeks after the last dose.\n15. If female and child-bearing potential, the patient must have a negative urine pregnancy test prior the first administration of the investigational product;\n16. Satisfactory general health status as determined by the investigator based on current medical status, medical history and physical examination.\n\nExclusion criteria\n\nPatients cannot be enrolled in the study if they meet any of the following criteria:\n\n1. Diagnosis of celiac disease or active or refractory tropical sprue;\n2. Presence of clinically significant intestinal adhesions and\u002For chronic abdominal pain that can interfere with the conduct of the study;\n3. Patients with current radiological (Radiography and\u002For CT) evidence of bowel dilatation or pseudo-obstruction;\n4. Active Crohn's disease as evaluated by standard procedures employed by the investigator;\n5. Inflammatory bowel disease (IBD) that required immunosuppressant therapy that has been introduced or changed within last 3 months or treatment with biologics within the last 6 months;\n6. Intestinal or other major surgery scheduled within the time frame of the study;\n7. Visible blood in the stool within the last 12 weeks;\n8. Clinical evidence of active radiation enteritis or scleroderma, contributing to the patient's stool volume;\n9. Compromised immune system (e.g., acquired immune deficiency syndrome \\[AIDS\\], severe combined immunodeficiency);\n10. Inadequate hepatic function: alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) and\u002For total bilirubin and\u002For alkaline phosphatases \\> 2 times the patient's average relative values in the last 3 months;\n11. Inadequate renal function: serum creatinine or blood urea nitrogen \\> 2 times the Upper Normal Limit (UNL);\n12. Urine sodium \\\u003C20 mmol\u002Fday;\n13. More than four SBS-related hospital admissions (unless one or more admissions were to rule out line sepsis) within the past 12 months or hospital admission within the last 4 weeks;\n14. Concurrent or past use of infliximab, growth hormone or growth factors such as native glucagon-like peptide-2 (GLP-2) or other biological therapy within the last 12 weeks;\n15. Use of systemic corticosteroids, methotrexate, cyclosporine, tacrolimus, sirolimus, octreotide, intravenous glutamine within the last 4 weeks;\n16. Use of antibiotics within the last week or active infection;\n17. History of alcohol abuse (Drinking more than 12 g\u002Fday of alcohol for women and 24 g\u002Fday of alcohol for men) or drug abuse within the last year;\n18. Pregnant or lactating women;\n19. History of psychiatric illnesses which lead to consider the patient as incapacitated and prevent him\u002Fher to provide informed consent;\n20. History of any other uncontrolled chronic or acute concomitant disease which, in the Investigator's opinion, would contraindicate study participation or confound interpretation of the results;\n21. Patient not capable of understanding or not willing to adhere to the study visit schedules and other protocol requirements;\n22. Participation in any other interventional clinical study within five times the half-life of the investigational medicinal product \u002F relevant metabolites (of the previous clinical study) or 4 weeks (whichever is longer) prior to screening;\n23. Known hypersensitivity\u002Fallergy to ANY component of the IP.","ALL","18 Years",{"count":20,"type":21},18,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A 24-week, randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety and tolerability of crofelemer in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon-in-continuity (CIC) requiring parenteral support (PS).\n\nBlinded study drug will be administered orally (or enterally) three times daily (TID) as a novel crofelemer formulation, Crofelemer Powder for Oral Solution, or a matching placebo powder formulation for oral solution.\n\nPatients will be randomized in a 1:1:1 ratio to crofelemer 3 mg\u002Fkg\u002Fdose TID, crofelemer 10 mg\u002Fkg\u002Fdose TID or placebo.",[27,28,29,30,31],"Short Bowel Syndrome","Malabsorption Syndromes","Short Gut Syndrome","Post-Op Complication","Functional Gastrointestinal Disorders",[27],"RECRUITING","2026-06-05",{"date":36,"type":37},"2026-06-09","ACTUAL",{"date":39,"type":37},"2025-05-29",{"date":41,"type":21},"2027-03",{"name":43,"class":44},"Napo Therapeutics, S.p.A.","INDUSTRY",8,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":66,"locationsCount":69},"100528074","perioperative-smart-device-monitoring-to-predict-complications-100528074","NCT06156033","Perioperative Smart Device Monitoring to Predict Complications","Perioperative Smart Device Monitoring as a Tool to Predict Post-operative Complications in Patients Undergoing Non Cardiac Intermediate and High-risk Surgery. A Single-center Prospective Observational Study","PreSmart","Patients will be recruited prospectively for a total of 50 patients.\n\nInclusion criteria are :\n\n* Patients scheduled for elective non cardiac intermediate or high-risk surgery under general anesthesia\n* 18 years of age or older\n* Capacity to understand french language\n\nExclusion criteria will be :\n\n\\- Patient refusal and\u002For inability to understand and sign informed consent",{"count":55,"type":21},50,"OBSERVATIONAL","This is a prospective, single-center, observational study designed to to quantify complications following non cardiac intermediate and high-risk surgery, and to identify digital biomarkers (collected pre, and post-operatively by a connected device) enabling early early identification of patients with post-operative complications. Patients will be invited to wear a smartdevice during the perioperative period, and will receive questionnaires about their their health status.",[30],"NOT_YET_RECRUITING","2026-03-24",{"date":62,"type":37},"2026-03-27",{"date":64,"type":21},"2026-04-01",{"date":41,"type":21},{"name":67,"class":68},"Centre Hospitalier Universitaire Vaudois","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":69},"100520974","early-phase-1-prevention-of-postoperative-atrial-fibrillation-poaf-using-intra-pericardial-amiodarone-100520974","NCT06063538","Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone","A Prospective Study Using Intra-Pericardial Amiodarone for the Prevention of Postoperative Atrial Fibrillation (POAF) in Patients Undergoing Cardiac Arterial Bypass Grafting and\u002For Valve Surgery","Inclusion Criteria:\n\n* Subject aged 20-85 years old.\n* Patients able to provide written informed consent, understand, and be willing to comply with study-related procedures.\n* Participants who are scheduled to undergo open-chest cardiac surgery via complete median sternotomy. Includes:\n\n  * Coronary artery bypass graft (CABG) and\u002For valve repair\u002Freplacement procedures (aortic, mitral, or tricuspid)\n  * Isolated ascending aortic aneurysm replacement\u002Frepair\n  * Note: Left atrial appendage (LAA) procedures are allowed if CABG and\u002For valve repair or replacement is the qualifying surgical procedure, but is not a qualifying surgical procedure on its own.\n* In sinus rhythm at the time of office visit and prior electrocardiogram (EKG) (note: continuous EKG monitoring for 48 hours is not required).\n\nExclusion Criteria:\n\n* Subject unable to give voluntary written informed consent, is unlikely to cooperate or is legally incompetent, including subjects who are institutionalized by court or official order, or in a dependency relationship with, testing center or investigator.\n* Any condition which could interfere with the subject's ability to comply with the study.\n* Ongoing participation in an interventional clinical study or during the preceding 30 days.\n* Female subjects who are pregnant, breastfeeding, were pregnant within the last three months, or are planning to become pregnant during the course of the study.\n* Active skin or deep infection at the site of implantation.\n* History of chronic wounds or wound-healing disorders.\n* Known connective tissue diseases (e.g. Ehlers-Danlos syndrome, Epidermolysis bullosa, Marfan syndrome, Osteogenesis imperfecta).\n* Immune-suppressed subjects, immune-deficiency subjects (properly managed diabetes mellitus is not an exclusion criterion).\n* Concomitant oral or IV systemic corticosteroid therapy and\u002For other constant anti-inflammatory therapies.\n* Patients already receiving amiodarone as a treatment for atrial fibrillation or ventricular arrhythmias.\n* Disease of the left pleura, previous intervention in the left pleural space, or chest deformity.\n* Subjects with end-stage chronic-renal disease \u002F dialysis.\n* STS (Society of Thoracic Surgeons Score) risk score \\>5.5% for 30 day mortality.","20 Years","85 Years",{"count":80,"type":21},63,[82],"EARLY_PHASE1","The purpose of this study is to evaluate the combination of CardiaMend, with the addition of amiodarone in the prevention of postoperative atrial fibrillation (POAF) in patients undergoing cardiac arterial bypass grafting (CABG) or valve surgery.",[85,30],"Atrial Fibrillation","2026-02-27",{"date":88,"type":37},"2026-03-02",{"date":90,"type":37},"2024-02-15",{"date":92,"type":21},"2027-06",{"name":94,"class":68},"University of Chicago",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":101,"minAge":18,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100621689","suprapubic-transverse-incision-with-rectus-release-for-upper-peritoneal-access-a-novel-dual-plane-technique-for-abdominal-wall-incision-in-complex-gynecological-surgery-100621689","NCT07373886","Suprapubic Transverse Incision With Rectus Release for Upper Peritoneal Access): A Novel Dual-Plane Technique for Abdominal Wall Incision in Complex Gynecological Surgery","Inclusion Criteria:\n\n1. Female patients aged 18-65 years\n2. Indication for open gynecologic surgery for benign or borderline pelvic or abdominopelvic masses\n3. Body Mass Index (BMI) ≥ 18 kg\u002Fm²\n4. Willing and able to provide informed consent and attend follow-up\n5. Mass size between 15-30 cm, which is considered optimal for the STIRRUP (Suprapubic Transverse Incision with Rectus Release for Upper Peritoneal access) technique due to the balance between exposure and minimal morbidity\n\nExclusion Criteria:\n\n1. Malignant tumors requiring upper abdominal visceral resection (liver, spleen, diaphragm)\n2. Emergency surgery\n3. Previous complex abdominal wall reconstruction with mesh\n4. Contraindication to general anesthesia\n5. Masses extending to the xiphisternum or measuring \\>30 cm\n6. Cases requiring supracolic omentectomy\n7. Planned lymphadenectomy (especially if comprehensive para-aortic lymph node dissection is required )\n8. Supramesocolic tumor extension or malignant ovarian tumors requiring hepatic resections, splenectomy, and diaphragmatic resection\n9. Severe comorbidities precluding elective surgery\n10. Pregnancy\n11. Previous extensive upper abdominal surgery","FEMALE","65 Years",{"count":55,"type":21},[105],"NA","This study aims to evaluate the clinical effectiveness, anatomical benefits, and postoperative outcomes of the STIRRUP incision (Suprapubic Transverse Incision with Rectus Release for Upper Peritoneal Access) by comparing outcomes with historically established benchmarks and published data from traditional abdominal wall incisions used in complex gynecologic surgery.",[30],"2026-01-21",{"date":110,"type":37},"2026-01-28",{"date":112,"type":21},"2026-02-01",{"date":114,"type":21},"2026-12-31",{"name":116,"class":68},"Cairo University",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":125,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":69},"100432757","phase-4-a-randomized-trial-of-lenient-versus-strict-arm-instruction-post-cardiac-device-surgery-100432757","NCT04915261","A Randomized Trial of Lenient Versus Strict Arm Instruction Post Cardiac Device Surgery","A Randomized Trial of Lenient Versus Strict Arm Instruction Post Cardiac Device Surgery - LENIENT","LENIENT","Inclusion Criteria:\n\n* all patients undergoing device surgery which includes implantation of at least one new endovascular lead\n\nExclusion Criteria:\n\n* Standalone CIED generator replacement\n* Subcutaneous implantable cardioverter defibrillators\n* Leadless endocardial pacemakers\n* Temporary permanent pacemakers",true,{"count":127,"type":21},6300,[129],"PHASE4","The purpose and objectives of this study is to investigate whether reducing the existing arm restrictions on patients who receive Cardiac Implantable Electronic Devices (CIED) will result in an improved patient experience post operatively and reduce complication rates. There are multiple and varied arm restriction instructions given to patients receiving CIED's with limited universally accepted protocols or advice on restrictions for patients following surgery.\n\nRestrictions such as arm immobilization, showering and weight lifting, in addition to contradictory advice between various hospitals and physicians, can negatively affect patient quality of life and increase patient anxiety with no current evidence for benefit. A cluster cross over randomized trial has been designed to test the comparative effectiveness of lenient vs strict arm restrictions for all patients receiving implantable devices.\n\nInstructions within both arms of this study are considered within reasonable practice in Canada.\n\nAll arm restriction instructions and parameters will be embedded within EPIC, nurses will teach the restriction in addition they will be provide to the patients via printed EPIC discharge summaries. Further links will be embedded in the After Visit Summary (AFS) printouts and my Chart for patients in EPIC. These instructions will be changed every 8 months, as per the crossover design of the trial. Additionally, both arms will utilize interactive voice recognition (IVR) to provide patients with further reminders and instruction on arm restrictions.\n\nAll patients are given standard of care instructions for follow up and complication assessment through the investigators' device clinic and 24\u002F7 on call nursing program.",[30],[133,134,135,136,137,138,139,140,141,142,143],"Cardiac","Implantable","Electronic","Device","Arm","Restriction","Post-operative","infection","dislodgement","hematoma","DVT","2025-12-05",{"date":146,"type":37},"2025-12-15",{"date":148,"type":37},"2021-08-19",{"date":150,"type":21},"2030-08-01",{"name":152,"class":68},"Ottawa Heart Institute Research Corporation",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":69},"100578831","phase-3-impact-of-varying-doses-of-prucalopride-on-improving-gut-function-recovery-after-elective-colorectal-surgery-100578831","NCT06816407","Impact of Varying Doses of Prucalopride on Improving Gut Function Recovery After Elective Colorectal Surgery","The Effect of Different Doses of Prucalopride on Improving Gut Function Recovery Following Elective Colorectal Surgery: a Randomized, Double-blind Study","Inclusion Criteria:\n\n* undergoing elective colorectal surgery, including but not limited to colectomy, rectal resection, and sigmoid resection.\n\nExclusion Criteria:\n\n* Emergency surgery\n* Total colectomy\n* Creation of a stoma\n* Pre-existing gastrointestinal disorders\n* Severe renal or hepatic impairment\n* Known hypersensitivity to prucalopride.","75 Years",{"count":162,"type":21},180,[164],"PHASE3","Postoperative ileus (POI) is a common complication after abdominal surgery, causing symptoms like nausea, vomiting, abdominal distension, and delayed passage of flatus and stool. Management remains challenging, with limited pharmacological options available. Prucalopride, a selective serotonin 5-HT4 receptor agonist, has shown promise in accelerating gastrointestinal recovery after surgery. However, the optimal timing and dosing for preventing POI remains unclear. Higher doses may provide more potent prokinetic effects in the postoperative setting. his study investigates if higher doses of prucalopride (4 mg) improve bowel function return and hospital stay in elective colorectal surgery patients compared to standard doses and placebo.",[30],[168,169],"pro kinetic","gut function recovery","2025-03-15",{"date":172,"type":37},"2025-03-19",{"date":174,"type":37},"2025-03-02",{"date":176,"type":21},"2025-05",{"name":178,"class":68},"Future University in Egypt",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":69},"100549891","irrisept-solution-for-instrumented-spine-surgery-100549891","NCT06439953","Irrisept Solution for Instrumented Spine Surgery","Impact of Prophylactic Use of Irrisept Irrigation System for Spinal Instrumentation","Inclusion Criteria:\n\n* Age: 18+ years old\n* Indications: deformity, oncologic, degenerative, trauma\n* Standard layer-by-layer closure\n* Locoregional flap-based closure\n\nExclusion Criteria:\n\n* Acute\u002Fchronic open wounds (spine or non-spine)\n* On-going non-spinal infection within 30 days of index operation\n* Concurrent antibiotic use (for spine or non-spine infections)\n* History of prior spinal infection\n* Allergy to vancomycin or chlorhexidine\n* Suspicion for osteomyelitis\n* Other surgery within 90 days post-operatively fromm index\n* Concurrent enrollment in other trial",{"count":187,"type":21},200,[105],"Various spine surgeons perform wound irrigation using saline mixed with vancomycin, relying on mechanical debridement of non-viable tissue, physical disruption of biofilm, and bacteriostatic effect against gram positive flora. When used as a powder, topical application of vancomycin has demonstrated increased risk of symptomatic seroma formation, which is an adverse outcome that often requires bedside or intra-operative aspiration. Broad-spectrum antiseptic agents, such as Irrisept, offer bacteriocidal properties to eliminate hardware inoculation, thereby minimizing the risk of deep space infection, while obviating the risk of seroma development.",[30,191,192,193,194,195,196,197],"Spine Surgery","Site Infection","Surgical Site Infection","Spinal Instrumentation","Index Spinal Instrumentation","Layer-by-Layer Closure","Locoregional Flap-Based Closure","2024-11-18",{"date":200,"type":37},"2024-11-20",{"date":202,"type":37},"2024-10-01",{"date":204,"type":21},"2026-09-30",{"name":206,"class":68},"Rhode Island Hospital",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":223,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":45},"100563208","phase-4-intravenous-acetaminophen-after-cardiac-surgery---definitive-study-100563208","NCT06613178","Intravenous Acetaminophen After Cardiac Surgery - Definitive Study","Intravenous Acetaminophen After Cardiac Surgery","IVACS","Inclusion Criteria:\n\ngreater or equal to 18\n\n* elective cardiac surgery\n* stable pre-operative\n* aorto-coronary bypass with or without 1 valve replacement.\n\nExclusion Criteria:\n\nRefusal by surgeon Requested late extubation by surgeon or anesthesia Intra-aortic balloon pump Mechanical cardiac support Sensitivity to acetaminophen Psychiatric history with current active treatment Alzheimer\\'s disease Seizure in previous 6 months Recent history of alcohol misuse Cognitive impairment\n\n\\-",{"count":216,"type":21},1100,[129],"Double blind, double dummy trial of the use of IV acetaminophen versus oral acetaminophen for the prevention of delirium after cardiac surgery. The underlying hypothesis is that better pain control and less use of narcotics will lead to a lower incidence of delirium from day 1 to 7 following cardiac surgery. Other important secondary outcomes are the total use of narcotics, ICU and hospital stay, improved cognitive function at 6 months and 1 year post surgery, NSAID use at each centre and associated NSAID complications.",[220,221,30,222],"Post Operative Delirium","Post Operative Pain","Post-cardiac Surgery",[224,225,226,227,228],"pain","post-operative care","cardiac surgery","narcotic","acetaminophen","2024-09-23",{"date":231,"type":37},"2024-09-25",{"date":233,"type":37},"2024-07-02",{"date":235,"type":21},"2027-12-15",{"name":237,"class":68},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":101,"minAge":77,"maxAge":245,"enrollmentInfo":246,"targetDuration":248,"studyType":56,"phases":4,"briefSummary":249,"conditions":250,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":4},"100560277","seroma-and-hematoma-rates-maxigesic-iv-vs-ketorolac-in-breast-cancer-surgery-100560277","NCT06575049","Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery","Comparative Analysis of Seroma and Hematoma Rates: MAXIGESIC vs. Ketorolac in Breast Cancer Surgery Patients","Inclusion Criteria:\n\n* Systemic performance status 0-2 according to ECOG criteria\n* Patients with adequate renal function: serum Cr 1.4 mg\u002FdL or less\n* Patients with adequate liver function Bilirubin, AST\u002FALT: 1.5 times or less of the upper limit of normal, Alkaline phosphatase: 1.8 times or less of the upper limit of normal\n* Patients undergoing total mastectomy with SLNB or ALND (mastectomy and axillary sentinel lymph node dissection)\n* Patients undergoing breast-conserving surgery with ALND (mastectomy and axillary dissection)\n* Patients who voluntarily decided to participate in this study and signed a written informed consent form\n\nExclusion Criteria:\n\n* Patients undergoing immediate reconstruction operation\n* Patients with drug allergies to painkillers and anti-inflammatory drugs\n* Patients with a physical condition that would interfere with understanding and submitting the consent form","70 Years",{"count":247,"type":21},60,"3 Months","The investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (NSAID) Ketorolac and MAXIGESIC. The investigators seek to determine the complication rates in patients receiving MAXIGESIC post-surgery, hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates.",[251,252,253,30],"Breast Cancer","Post-Operative Hematoma","Seroma as Procedural Complication","2024-09-02",{"date":256,"type":37},"2024-09-19",{"date":258,"type":21},"2025-05-01",{"date":260,"type":21},"2026-02-20",{"name":262,"class":68},"Seoul National University Hospital",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":271,"minAge":4,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":280,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":69},"100369024","artery-embolization-vs-operation-of-benign-prostate-hyperplasia-100369024","NCT04084938","Artery Embolization vs Operation of Benign Prostate Hyperplasia","Prostatic Artery Embolization vs Transurethral Resection of the Prostate or Open Prostatectomy in Patients With Symptomatic Benign Prostatic Hyperplasia","NORTAPE","Inclusion Criteria:\n\n* LUTS from Benign Prostate Hyperplasia (BPH) with moderate and severe IPSS score (IPSS \\> 8) and QoL = or \\>3\n* and refractory to medical treatment for at least 6 months or the patient is unwilling to accept medical treatment\n* or BPH using permanent or intermittent catheterization\n* Prostate volume \\> 50 ml\n* Signed informed consent\n\nExclusion Criteria:\n\n* Urological disorders: evidence of clinically significant prostate cancer \\[as defined by START criteria\\] on prostate biopsy (27,28), prostatitis (29,30), detrusor-sphincter dyssynergia or evidence of neurogenic bladder, urethral strictures, bladder neck contracture, bladder stone or bladder cancer\n* Renal insufficiency defined as Glomerular Filtration Rate \\\u003C 30 ml\u002Fmin\u002F1,73m2\n* Known severe reactions to iodine-based contrast or gadolinium-based contrast\n* Previous prostate operation\n* CT examination reveals no access to the prostate arteries.","MALE",{"count":273,"type":21},140,[105],"Aim of the study is to compare prostate artery embolization (PAE) to the established surgical treatment for patient acceptance, morbidity, complications, and the functional outcomes. To compare length of stay, hospital costs and time for recovery. 140 patients will be randomized to PAE or surgery. Patients should suffer from lower urinary tract symptoms (LUTS), be candidates for both treatments and willing to undergo both procedures. Before randomization computed tomography angiography of the pelvic arteries is done to select eligible patients. Magnetic resonance imaging of prostate rules out possible cancer. The PAE is done in the angio suite in the radiology department injecting small particles into the prostate arteries. The surgery is done in the operation room in the urology department according to established procedures. Clinical follow-up include clinical visit after 3 months, 1 and 5 years. Acute as well as long term complications will be recorded.",[277,30,278,279],"Benign Prostatic Hyperplasia","Embolization Therapeutic","Transurethral Resection of Prostate Syndrome",[281,282,283,284,285],"Prostate","Embolization","Complication","Operation","Randomization","2023-12-26",{"date":288,"type":37},"2023-12-27",{"date":290,"type":37},"2019-09-01",{"date":292,"type":21},"2027-12-31",{"name":294,"class":68},"Oslo University Hospital"]